Futura Medical PLC Further Positive Market Research Data for MED2002 (6261T)
16 October 2017 - 5:00PM
UK Regulatory
TIDMFUM
RNS Number : 6261T
Futura Medical PLC
16 October 2017
For immediate release 16 October 2017
Futura Medical plc
("Futura" or "the Company")
Further Positive Market Research Data for MED2002
Futura Medical plc (AIM: FUM), the innovative healthcare company
focused on advanced transdermal technology, announces that it has
recently completed primary market research indicating that more
than 60 per cent of physicians in the US consider that MED2002, the
Company's novel gel for erectile dysfunction ("ED"), is an
improvement over current ED therapies.
The research, carried out by leading healthcare strategy firm
Cello Health Consulting ("Cello"), also revealed that at least 10
per cent of ED patients were contra-indicated to PDE5 inhibitors
(such as Viagra(R) or Cialis(R) ) because of their existing nitrate
medication, a larger percentage than the 7.5 per cent historically
stated by the Company based on previously conducted research.
The results of the survey are based on interviews with a total
of 200 doctors in the US, Germany and France. To qualify for the
interview each of the doctors had to been in general practice for
at least five years and treated a minimum of 15 ED patients per
month. Previously commissioned research by Futura into the
potential size of both the prescription and over the counter (OTC)
markets showed the significant commercial potential of the product.
The Cello research was commissioned to gain insight into the
attitudes of front line doctors who would be prescribing or
recommending MED2002 to their patients - a crucial part of the
sales process.
Of the doctors interviewed, 64 per cent in the US, 60 per cent
in Germany and 54 per cent in France considered that MED2002 is an
improvement over current ED treatments, which are dominated by PDE5
inhibitors.
The results of the survey show that MED2002 could capture
between a quarter and a third of the estimated ED patients in the
US, including newly diagnosed and existing patients. The rapid
speed of onset, of normally within five minutes, and the
spontaneity associated with the use of the product were given by
doctors as key reasons for expected patient use of the product.
The research focused on MED2002 as a treatment launched in a
generic prescription market and its results were consistent, in
terms of the differentiation of the product, with earlier research
commissioned by the Company into MED2002 as a prescription medicine
and, for later in its product cycle, as an OTC medicine.
James Barder, Futura's Chief Executive, said: "We are delighted
by the results of this new survey, which not only reinforce the
potential of MED2002 identified in our two earlier surveys but
provide some important additional insights. In particular, the
number of ED patients contra-indicated to PDE5 inhibitors because
of their existing nitrate medication is potentially much greater
than we had previously thought.
"MED2002's rapid speed of onset helps to restore intimacy and
spontaneity for the ED patient and his partner and this unique
proposition clearly addresses an unmet need with at least two
thirds of the doctors interviewed stating this is a very appealing
feature. It is also particularly encouraging that more than half of
all the doctors interviewed in the survey considered MED2002 to be
an improvement over currently available ED therapies. Our clinical
and commercial development of MED2002 is progressing well and we
look forward to providing a further update shortly."
For any further information please contact:
Futura Medical plc
James Barder, Chief Executive Tel: +44 (0)1483 685
670
mail to: james.barder@futuramedical.com www.futuramedical.com
N+1 Singer (Nominated Adviser
and Broker)
Aubrey Powell / Liz Yong Tel:+44 (0) 20 7496 3000
For media enquiries please
contact:
Buchanan
Mark Court / Sophie Cowles Tel: +44 (0)20 7466 5000
/ Stephanie Watson
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops
innovative products for consumer healthcare. The Company is
developing a portfolio of products and its strategy is to license
their manufacture and distribution to major pharmaceutical and
healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGMMMGMKLGNZZ
(END) Dow Jones Newswires
October 16, 2017 02:00 ET (06:00 GMT)
Futura Medical (LSE:FUM)
Historical Stock Chart
From Apr 2024 to May 2024
Futura Medical (LSE:FUM)
Historical Stock Chart
From May 2023 to May 2024